What amount sold does Adjuvance Technologies Inc. report in Form D filings?

The latest linked filings report $13.4M sold across 2 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Adjuvance Technologies Inc.'s most recent SEC filing?

Adjuvance Technologies Inc.'s most recent Form D filing was on 2019-11-22.

How many investors does Adjuvance Technologies Inc. have?

The most recent Form D filing lists 28 investor(s).

What type of securities does Adjuvance Technologies Inc. offer?

Adjuvance Technologies Inc.'s SEC Form D filings indicate equity offerings.

Adjuvance Technologies Inc.

CIK: 0001652786·Biotechnology·Lincoln, NE·Corporation

Reported Sold

$13,374,886

Total Filings

Identified Offerings

Last Filed

Nov 22, 2019

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Nov 22, 2019Form D/A — Amendment

Reported sold: $10,657,192 · Target: $24,657,194

Rule 506(b)·28 investors

Sep 24, 2019Form D — New notice

Reported sold: $10,657,192 · Target: $24,657,194

Rule 506(b)·28 investors

Nov 14, 2016Form D/A — Amendment

Reported sold: $2,717,694 · Target: $7,000,000

Rule 506(b)·15 investors

Changed: Reported amount sold, Reported investors

Sep 22, 2015Form D — New notice

Reported sold: $1,000,000 · Target: $7,000,000

Rule 506(b)·1 investor

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

50%

Latest reported sold across 2 identified offerings

$13,374,886

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Mary Gin

Related Person

Appears on 2 filings

Phil Livingston

Related Person

Appears on 2 filings

Christopher Frigon

Related Person

Appears on 2 filings

Gregory Poland

Related Person

Appears on 2 filings

John Gallo

Related Person

Appears on 2 filings

Tyler Martin

Related Person

Appears on 2 filings

Jeffrey Gardner

Related Person

Appears on 2 filings

Isaac Cheng

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 22, 2019	Amendment	$24,657,194	$10,657,192	28
Sep 24, 2019	New	$24,657,194	$10,657,192	28
Nov 14, 2016	Amendment	$7,000,000	$2,717,694	15
Sep 22, 2015	New	$7,000,000	$1,000,000	1

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Nuclein, LLC

Biotechnology

Offering target: $26,114,842

Filed Oct 27, 2026